Saturday, October 31, 2026

Boston Properties Stock Bearish Momentum With A 31% Slide In The Last 21 Sessions

Boston Properties Stock Bearish Momentum With A 31% Slide In The Last 21 Sessions

(VIANEWS) - Shares of Boston Properties (NYSE: BXP) dropped by a staggering 31.12% in 21 sessions from $73.07 to $50.33 at 13:10 EST on Friday, following the last session's downward trend. NYSE is dropping 1.55% to $14,601.77, following the last session's upward trend.

Boston Properties's last close was $53.51, 59.8% below its 52-week high of $133.11.

About Boston Properties

Boston Properties (NYSE:BXP) is the largest publicly-held developer and owner of Class A office properties in the United States, concentrated in five markets - Boston, Los Angeles, New York, San Francisco and Washington, DC. The Company is a fully integrated real estate company, organized as a real estate investment trust (REIT), that develops, manages, operates, acquires and owns a diverse portfolio of primarily Class A office space. The Company's portfolio totals 51.2 million square feet and 196 properties, including six properties under construction/redevelopment.

Earnings Per Share

As for profitability, Boston Properties has a trailing twelve months EPS of $2.93.

PE Ratio

Boston Properties has a trailing twelve months price to earnings ratio of 17.19. Meaning, the purchaser of the share is investing $17.19 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.45%.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on Dec 28, 2022, the estimated forward annual dividend rate is 3.92 and the estimated forward annual dividend yield is 5.37%.

More news about Boston Properties (BXP).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com